Table 1 Modified weight factors (in percent) for the items of the translatability score in the different disease areas
From: Translatability score revisited: differentiation for distinct disease areas
|  | Original = cardio-vascular | Oncology | Psychiatric | Anti-viral | Anti-bacterial/fungal | Monogenetic orphans |
|---|---|---|---|---|---|---|
Aspect | ||||||
Starting evidence | ||||||
  In vitro data including animal genetics | 2 | 2 | 1 | 9 | 3 | 2 |
  In vivo data including animal genetics | 3 | 1 | 1 | 1 | 5 | 2 |
  Animal disease models | 3 | 5 | 1 | 1 | 5 | 2 |
  Data from multiple species | 3 | 1 | 1 | 1 | 1 | 2 |
Human evidence | ||||||
  Genetics | 5 | 5 | 4 | 4 | 4 | 20 |
  Model compounds | 13 | 10 | 26 | 12 | 12 | 2 |
  Clinical trials | 13 | 11 | 26 | 12 | 12 | 10 |
Biomarkers for efficacy and safety prediction | ||||||
  Biomarker grading | 24 | 28 | 10 | 23 | 22 | 23 |
  Biomarker development | 13 | 17 | 5 | 12 | 11 | 12 |
Proof-of-mechanism, proof-of-principle and proof of concept testing | ||||||
  Biomarker strategy | 5 | 5 | 7 | 5 | 5 | 5 |
  Surrogate or endpoint strategy | 8 | 2 | 12 | 7 | 7 | 7 |
Personalized medicine aspects | ||||||
  Disease sub-classification and responder concentration | 3 | 7 | 2 | 9 | 9 | 9 |
  Pharmacogenetics | 5 | 6 | 4 | 4 | 4 | 4 |
  Sum | 100 | 100 | 100 | 100 | 100 | 100 |